Pharmacological Activities of Fingerroot Extract and Its Phytoconstituents Against SARS-CoV-2 Infection in Golden Syrian Hamsters.
Boesenbergia rotunda
COVID-19
SARS-CoV-2
Zingiberaceae
hamster
panduratin A
Journal
Journal of experimental pharmacology
ISSN: 1179-1454
Titre abrégé: J Exp Pharmacol
Pays: New Zealand
ID NLM: 101530345
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
07
2022
accepted:
24
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
The outbreak of COVID-19 has led to the suffering of people around the world, with an inaccessibility of specific and effective medication. Fingerroot extract, which showed in vitro anti-SARS-CoV-2 activity, could alleviate the deficiency of antivirals and reduce the burden of health systems. In this study, we conducted an experiment in SARS-CoV-2-infected hamsters to determine the efficacy of fingerroot extract in vivo. The infected hamsters were orally administered with vehicle control, fingerroot extract 300 or 1000 mg/kg, or favipiravir 1000 mg/kg at 48 h post-infection for 7 consecutive days. The hamsters (n = 12 each group) were sacrificed at day 2, 4 and 8 post-infection to collect the plasma and lung tissues for analyses of viral output, lung histology and lung concentration of panduratin A. All animals in treatment groups reported no death, while one hamster in the control group died on day 3 post-infection. All treatments significantly reduced lung pathophysiology and inflammatory mediators, PGE Fingerroot extract was shown to be a potential of reducing lung inflammation and cytokines in hamsters. Further studies of the full pharmacokinetics and toxicity are required before entering into clinical development.
Sections du résumé
Background
UNASSIGNED
The outbreak of COVID-19 has led to the suffering of people around the world, with an inaccessibility of specific and effective medication. Fingerroot extract, which showed in vitro anti-SARS-CoV-2 activity, could alleviate the deficiency of antivirals and reduce the burden of health systems.
Aim of Study
UNASSIGNED
In this study, we conducted an experiment in SARS-CoV-2-infected hamsters to determine the efficacy of fingerroot extract in vivo.
Materials and Methods
UNASSIGNED
The infected hamsters were orally administered with vehicle control, fingerroot extract 300 or 1000 mg/kg, or favipiravir 1000 mg/kg at 48 h post-infection for 7 consecutive days. The hamsters (n = 12 each group) were sacrificed at day 2, 4 and 8 post-infection to collect the plasma and lung tissues for analyses of viral output, lung histology and lung concentration of panduratin A.
Results
UNASSIGNED
All animals in treatment groups reported no death, while one hamster in the control group died on day 3 post-infection. All treatments significantly reduced lung pathophysiology and inflammatory mediators, PGE
Conclusion
UNASSIGNED
Fingerroot extract was shown to be a potential of reducing lung inflammation and cytokines in hamsters. Further studies of the full pharmacokinetics and toxicity are required before entering into clinical development.
Identifiants
pubmed: 36699694
doi: 10.2147/JEP.S382895
pii: 382895
pmc: PMC9869698
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13-26Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023 Kongratanapasert et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Front Immunol. 2020 May 28;11:1239
pubmed: 32574273
PLoS Pathog. 2021 Jul 15;17(7):e1009705
pubmed: 34265022
Front Pharmacol. 2021 Mar 24;12:611408
pubmed: 33841143
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Bioorg Med Chem. 2006 Mar 15;14(6):1710-4
pubmed: 16263298
Evid Based Complement Alternat Med. 2012;2012:473637
pubmed: 23243448
J Nat Prod. 2021 Apr 23;84(4):1261-1270
pubmed: 33844528
J Ethnopharmacol. 2020 Oct 28;261:113104
pubmed: 32565307
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Viruses. 2020 Jul 20;12(7):
pubmed: 32698441
Nat Rev Drug Discov. 2021 Mar;20(3):200-216
pubmed: 33510482
Lancet Infect Dis. 2021 Oct;21(10):1352-1354
pubmed: 34454652
J Virol. 2020 Oct 14;94(21):
pubmed: 32817221
Lab Anim. 2020 Feb;54(1):99-110
pubmed: 31665969
Nat Commun. 2021 Aug 11;12(1):4869
pubmed: 34381043
Pharmacogn Rev. 2017 Jan-Jun;11(21):27-30
pubmed: 28503050
Sci Rep. 2020 Nov 17;10(1):19963
pubmed: 33203926
Front Pediatr. 2021 Mar 30;8:607647
pubmed: 33859967
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
Front Immunol. 2021 Feb 18;12:613422
pubmed: 33679753
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
PLoS One. 2021 Aug 4;16(8):e0255335
pubmed: 34347801
PLoS Pathog. 2022 Apr 6;18(4):e1010468
pubmed: 35385545
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32269085
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Planta Med. 2003 Dec;69(12):1102-8
pubmed: 14750025
Front Plant Sci. 2020 Nov 16;11:589998
pubmed: 33304368
Nat Commun. 2021 Mar 19;12(1):1735
pubmed: 33741945
Nat Commun. 2020 Nov 17;11(1):5859
pubmed: 33203833
JCI Insight. 2020 Dec 3;5(23):
pubmed: 33090972
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965
pubmed: 33037151